

**Clean Copy of Claims, as Amended
in the Amendment Filed in Response to the
Office Action Dated 13 February 2002**

8. (Twice Amended) An isolated polypeptide that exhibits a TANGO 294 activity and is selected from the group consisting of:

a) a fragment of a polypeptide which has an amino acid sequence comprising any one of SEQ ID NOs: 47, 49, and the amino acid sequence encoded by clone EpT294, which was deposited as ATCC[®] Accession Number 207220, wherein the fragment comprises at least 40 contiguous amino acid residues of either SEQ ID NO: 47 or the amino acid sequence encoded by clone EpT294;

b) a variant of a polypeptide that has an amino acid sequence comprising any one of SEQ ID NOs: 47, 49, and the amino acid sequence encoded by clone EpT294, wherein the polypeptide is encoded by a nucleic acid molecule which hybridizes to a nucleic acid molecule having the nucleotide sequence of any one of SEQ ID NOs: 45, 46, and clone EpT294, or a complement thereof, under stringent conditions, wherein the stringent conditions comprise hybridization in $6 \times$ sodium chloride/sodium citrate buffer (SSC) at 45°C, followed by washing in $0.2 \times$ SSC comprising 0.1% SDS at 65°C; and

c) a polypeptide which is encoded by a nucleotide sequence having a portion which is at least 90% identical to any one of SEQ ID NOs: 45, 46, and the nucleotide sequence of clone EpT294.

28. (Amended) The isolated polypeptide of claim 8, wherein the TANGO 294 activity is selected from the group consisting of

- i) ability to modulate absorption of a lipid;
- ii) ability to modulate metabolism of a lipid;
- iii) ability to modulate transport of a lipid; and

iv) lipase activity.

47. (New) The isolated polypeptide of claim 28, wherein the TANGO 294 activity is lipase activity.

9. (Twice Amended) The isolated polypeptide of claim 8, having the amino acid sequence of any one of SEQ ID NOs: 47, 49, and the amino acid sequence encoded by clone EpT294.

40. The isolated polypeptide of claim 9, having the amino acid sequence of SEQ ID NO: 47.

41. The isolated polypeptide of claim 9, having the amino acid sequence of SEQ ID NO: 49.

10. The polypeptide of claim 8, wherein the amino acid sequence of the polypeptide further comprises heterologous amino acid residues.

24. (Amended) The isolated polypeptide of claim 8,

wherein the isolated polypeptide is a fragment of a polypeptide which has an amino acid sequence comprising any one of SEQ ID NOs: 47, 49, and the amino acid sequence encoded by clone EpT294, and

wherein the sequence of the fragment comprises at least 40 contiguous amino acid residues of SEQ ID NO: 47.

25. (Amended) The isolated polypeptide of claim 24, wherein the sequence of the fragment comprises at least 75 contiguous amino acid residues of SEQ ID NO: 47.

26. (Amended) The isolated polypeptide of claim 24, wherein the sequence of the fragment comprises at least 150 contiguous amino acid residues of SEQ ID NO: 47.

29. The isolated polypeptide of claim 24, admixed with a pharmaceutically acceptable carrier.

30. (Amended) The isolated polypeptide of claim 8,

wherein the isolated polypeptide is a variant of a polypeptide that has an amino acid sequence comprising any one of SEQ ID NOs: 47, 49, and the amino acid sequence encoded by clone EpT294, and

wherein the polypeptide is encoded by a nucleic acid molecule which hybridizes to a nucleic acid molecule having the nucleotide sequence of any one of SEQ ID NOs: 45, 46, and clone EpT294, or a complement thereof, under stringent conditions, wherein the stringent conditions comprise hybridization in $6 \times$ sodium chloride/sodium citrate buffer (SSC) at 45°C , followed by washing in $0.2 \times$ SSC comprising 0.1% SDS at 65°C .

33. The isolated polypeptide of claim 30, wherein the isolated polypeptide exhibits a property selected from the group consisting of:

- i) ability to modulate absorption of a lipid;
- ii) ability to modulate metabolism of a lipid; and
- iii) ability to modulate transport of a lipid.

34. The isolated polypeptide of claim 30, admixed with a pharmaceutically acceptable carrier.

35. (Amended) The isolated polypeptide of claim 8, wherein the isolated polypeptide is encoded by a nucleotide sequence having a portion which is at least 90% identical to any one of SEQ ID NOs: 45, 46, and the nucleotide sequence of clone EpT294.

36. The isolated polypeptide of claim 35, wherein the portion is at least 95% identical to SEQ ID NO: 46.

38. The isolated polypeptide of claim 35, wherein the isolated polypeptide exhibits a property selected from the group consisting of

- i) ability to modulate absorption of a lipid;
- ii) ability to modulate metabolism of a lipid; and
- iii) ability to modulate transport of a lipid.

39. The isolated polypeptide of claim 35, admixed with a pharmaceutically acceptable carrier.

42. An isolated polypeptide that exhibits lipase activity, wherein the amino acid sequence of the isolated polypeptide comprises a portion that is at least 90% identical to 150 contiguous amino acid residues of SEQ ID NO: 47.

43. The isolated polypeptide of claim 42, wherein the portion is at least 95% identical to 200 contiguous amino acid residues of SEQ ID NO: 49.

44. The isolated polypeptide of claim 42, wherein the amino acid sequence of the isolated polypeptide is at least 90% identical to any one of SEQ ID NO: 47, residues 15-423 of SEQ ID NO: 47, and SEQ ID NO: 49.

45. The isolated polypeptide of claim 42, admixed with a pharmaceutically acceptable carrier.

46. An isolated polypeptide that exhibits a property selected from the group consisting of

- i) ability to modulate absorption of a lipid;

ii) ability to modulate metabolism of a lipid; and

iii) ability to modulate transport of a lipid,

wherein the amino acid sequence of the isolated polypeptide comprises a portion that is at least 90% identical to 150 contiguous amino acid residues of SEQ ID NO: 47.